Xuemin Wang

Dr. Xuemin Wang

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
XQXiaocui Qin
Xiaocui Qin
QWQiaoqi Wu
Qiaoqi Wu
LLLifang Lin
Lifang Lin
ASAimin Sun
Aimin Sun
SLShuhu Liu
Shuhu Liu
XWXuemin Wang
Xuemin Wang

18 November 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
XGXi Gu
Xi Gu
ALAili Li
Aili Li
SLShuhu Liu
Shuhu Liu
LLLifang Lin
Lifang Lin
SXShuang Xu
Shuang Xu
XWXuemin Wang
Xuemin Wang

9 July 2020 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
YHYanjun Huang
Yanjun Huang
LSLirong Sun
Lirong Sun
SZShuzhen Zhu
Shuzhen Zhu
LXLiu Xu
Liu Xu
SLShuhu Liu
Shuhu Liu
XWXuemin Wang
Xuemin Wang
Parkinson’s disease (PD) is one of the most prevalent and life-threatening neurodegenerative disease and mainly characterized by lack of sufficient dopaminergic neurons in the substantia nigra pars compacta (SNc). Although current treatments help to alleviate clinical symptoms, effective therapies preventing neuronal loss remain scarce. Tovophyllin A (TA), one of the xanthones extracted from Garcinia mangostana L. (GM), has recently been reported to play a beneficial role in the therapy of neurodegenerative diseases. In our research, we explored whether TA has protective effects on dopaminergic neurons in PD models. We found that TA significantly reduced apoptotic cell death in primary cortical neurons treated with 1-methyl-4-phenyl pyridinium (MPP+) or paraquat (PQ) in the in vitro PD model. In an in vivo acute PD model induced by 1-methyl4-phenyl-1,2,3,5-tetrahydropyridine (MPTP) treatment, TA also attenuated the resulting behavioral dysfunctions and dopaminergic neuron loss. In the collected brain tissues, TA increased the phosphorylation of Akt and GSK-3β, which may be related to TA-mediated dopaminergic neuronal protective effects. In summary, our results illustrated that TA is a powerful cytoprotective agent for dopaminergic neurons in the MPTP-induced PD model, suggesting TA as a possible therapeutic candidate for PD.

1 February 2020 in Neuropharmacology
Verified
Journal Article
Closed access
XSXiaohong Su
Xiaohong Su
XGXi Gu
Xi Gu
ZZZhiduo Zhang
Zhiduo Zhang
WLWeipeng Li
Weipeng Li
XWXuemin Wang
Xuemin Wang

11 January 2017 in Neurological Sciences
Verified
Journal Article
Closed access
ZZZhi-Hua Zhou
Zhi-Hua Zhou
YWYun-Fan Wu
Yun-Fan Wu
XWXuemin Wang
Xuemin Wang
YHYong-Zhu Han
Yong-Zhu Han

26 July 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
ZHZhuoyi He
Zhuoyi He
HCHouminji Chen
Houminji Chen
YZYongsheng Zhong
Yongsheng Zhong
QYQihang Yang
Qihang Yang
XWXuemin Wang
Xuemin Wang
YGYanwu Guo
Yanwu Guo
This study aimed to explore whether microRNA (miR) 223 affects microglial autophagy by targeting autophagy-related 16-like 1 (ATG16L1) in the kainic acid (KA) model of temporal lobe epilepsy (TLE). The miRNA and mRNA expression levels were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), and the protein expression was investigated using western blotting. A dual-luciferase reporter assay was used to test the direct interaction between miR 223 and ATG16L1. In situ hybridization was performed to measure the hippocampal expression of miR 223. We used immunofluorescence staining to assess the expression of ATG16L1 and microtubule-associated protein light chain 3 (LC3) in the murine hippocampal microglia. Inhibitor of miR 223 was utilized to investigate the role of miR 223 in TLE, and the epileptic activity was assessed using electroencephalography (EEG). The autophagosomes were observed by transmission electron microscopy. In patients with TLE, the murine KA model of TLE, and the KA-stimulated BV2 cells, miR 223, and sequestosome 1 (SQSTM1/P62) expressions were remarkably increased, whereas ATG16L1 and LC3 levels were significantly decreased. Using a dual-luciferase reporter assay, ATG16L1 was determined as a direct target of miR 223. Treatment with antagomir 223 alleviated epilepsy, prevented abnormalities in EEG recordings and increased the ATG16L1 and LC3 levels in KA-treated mice. Inhibition of miR 223 induced increased autophagy in BV2 cells upon Rapamycin stimulation. These findings show that miR 223 affects microglial autophagy via ATG16L1 in the KA model of TLE. The miR 223/ATG16L1 pathway may offer a new treatment option for TLE.